Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of $1.05 billion. The enterprise value is $1.07 billion.
Important Dates
The last earnings date was Tuesday, September 30, 2025, after market close.
Earnings Date | Sep 30, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Nanobiotix has 48.21 million shares outstanding. The number of shares has increased by 10.33% in one year.
Current Share Class | n/a |
Shares Outstanding | 48.21M |
Shares Change (YoY) | +10.33% |
Shares Change (QoQ) | +0.03% |
Owned by Insiders (%) | 3.30% |
Owned by Institutions (%) | 5.99% |
Float | 30.85M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 87.65 |
Forward PS | 26.14 |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 89.85 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.63
Current Ratio | 0.63 |
Quick Ratio | 0.58 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -5.19 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -41.64% |
Return on Invested Capital (ROIC) | -567.28% |
Return on Capital Employed (ROCE) | 245.90% |
Revenue Per Employee | $110,470 |
Profits Per Employee | -$561,569 |
Employee Count | 108 |
Asset Turnover | 0.15 |
Inventory Turnover | n/a |
Taxes
Income Tax | -43,453 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +338.92% in the last 52 weeks. The beta is 1.58, so Nanobiotix's price volatility has been higher than the market average.
Beta (5Y) | 1.58 |
52-Week Price Change | +338.92% |
50-Day Moving Average | 10.55 |
200-Day Moving Average | 5.50 |
Relative Strength Index (RSI) | 84.16 |
Average Volume (20 Days) | 113,541 |
Short Selling Information
Short Interest | 11,042 |
Short Previous Month | 23,504 |
Short % of Shares Out | 0.02% |
Short % of Float | 0.04% |
Short Ratio (days to cover) | 0.76 |
Income Statement
In the last 12 months, Nanobiotix had revenue of $11.93 million and -$60.65 million in losses. Loss per share was -$1.28.
Revenue | 11.93M |
Gross Profit | 11.93M |
Operating Income | -51.59M |
Pretax Income | -60.69M |
Net Income | -60.65M |
EBITDA | -51.49M |
EBIT | -51.59M |
Loss Per Share | -$1.28 |
Full Income Statement Balance Sheet
The company has $33.84 million in cash and $60.18 million in debt, giving a net cash position of -$26.33 million or -$0.55 per share.
Cash & Cash Equivalents | 33.84M |
Total Debt | 60.18M |
Net Cash | -26.33M |
Net Cash Per Share | -$0.55 |
Equity (Book Value) | -80.98M |
Book Value Per Share | -1.68 |
Working Capital | -27.18M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$36.55 million and capital expenditures -$595,420, giving a free cash flow of -$37.04 million.
Operating Cash Flow | -36.55M |
Capital Expenditures | -595,420 |
Free Cash Flow | -37.04M |
FCF Per Share | -$0.77 |
Full Cash Flow Statement Margins
Gross Margin | 100.00% |
Operating Margin | -432.39% |
Pretax Margin | -508.71% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -10.33% |
Shareholder Yield | -10.33% |
Earnings Yield | -5.80% |
FCF Yield | -3.54% |
Analyst Forecast
The average price target for Nanobiotix is $8.00, which is -64.88% lower than the current price. The consensus rating is "Strong Buy".
Price Target | $8.00 |
Price Target Difference | -64.88% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Nanobiotix has an Altman Z-Score of -2.82 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -2.82 |
Piotroski F-Score | 1 |